Bionano Genomics - BNGO Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bionano Genomics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BNGO shares.
View BNGO analyst ratings or view top-rated stocks.

3 brokerages have issued 1 year price objectives for Bionano Genomics' shares. Their BNGO share price forecasts range from $7.00 to $12.00. On average, they anticipate the company's stock price to reach $10.33 in the next year. This suggests a possible upside of 443.9% from the stock's current price.
View analysts price targets for BNGO or view top-rated stocks among Wall Street analysts.

Bionano Genomics' stock was trading at $2.99 on January 1st, 2022. Since then, BNGO shares have decreased by 36.5% and is now trading at $1.90.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our BNGO earnings forecast.

Bionano Genomics, Inc. (NASDAQ:BNGO) issued its earnings results on Thursday, August, 4th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.01. The business had revenue of $6.67 million for the quarter, compared to the consensus estimate of $6.20 million. Bionano Genomics had a negative net margin of 453.68% and a negative trailing twelve-month return on equity of 33.21%.

Bionano Genomics updated its FY 2022 earnings guidance on Thursday, September, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $24.00 million-$27.00 million, compared to the consensus revenue estimate of $26.20 million.

17 employees have rated Bionano Genomics Chief Executive Officer R. Erik Holmlin on Glassdoor.com. R. Erik Holmlin has an approval rating of 73% among the company's employees. 71.0% of employees surveyed would recommend working at Bionano Genomics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bionano Genomics investors own include Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI), Zosano Pharma (ZSAN), ADMA Biologics (ADMA), CNBX Pharmaceuticals (CNBX), KushCo (KSHB), Aeterna Zentaris (AEZS) and OrganiGram (OGI).

(BNGO) raised $16 million in an initial public offering (IPO) on the week of August 20th 2018. The company issued 2,500,000 shares at a price of $6.00-$7.00 per share. Roth Capital Partners and Maxim Group served as the underwriters for the IPO and LifeSci Capital was co-manager.

Bionano Genomics trades on the NASDAQ under the ticker symbol "BNGO."

Shares of BNGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BNGO stock can currently be purchased for approximately $1.90.

Bionano Genomics (NASDAQ:BNGO) has a market capitalization of $550.43 million and generates $17.98 million in revenue each year. The company earns $-72,430,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

The company employs 299 workers across the globe.

Bionano Genomics' mailing address is 9540 TOWNE CENTRE DRIVE SUITE 100, SAN DIEGO CA, 92121. The official website for the company is www.bionanogenomics.com. The company can be reached via phone at (858) 888-7600 or via email at arr@lifesciadvisors.com.